Knight Therapeutics TAVALISSE Colombia Approval
Analysis based on 7 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The approval is a positive regulatory milestone for Knight Therapeutics, potentially expanding its revenue base in Latin America and strengthening its product portfolio. It may also benefit Bora Pharmaceuticals through increased royalties or milestone payments, though the immediate market impact is likely modest given the drug's niche indication.
Knight Therapeutics Inc. announced on September 1, 2026, that it received regulatory approval from Colombia — National Food and Drug Surveillance Institute, Colombia's health regulatory agency, for TAVALISSE (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin. This approval marks a significant step in expanding access to the drug in Latin America, following Knight's 2022 agreement with Bora Pharmaceuticals for exclusive commercialization rights in the region. Knight has submitted TAVALISSE for approval in Brazil, Colombia, Mexico, Argentina, and Paraguay, launched it in Mexico in May 2026, and expects launches in Brazil in Q4 2026 and Colombia in H1 2027.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard